Localizing infection with a technetium-99m-labeled peptide: initial results.
In vitro-labeled leukocyte imaging is useful for the detection of infection, but an in vivo labeling method is preferable. This study sought to evaluate the safety and efficacy of a leukocyte-avid peptide for the detection of infection, to determine the effects of peptide dose on performance and to compare the peptide with in vitro-labeled leukocytes. A 23-amino acid peptide, P483, containing the platelet factor-4 heparin-binding sequence, was labeled with 99mTc and complexed with heparin (P483H). Thirty patients were injected with 29 microg (n = 11), 145 microg (n = 10) or 290 microg (n = 9) of labeled peptide, and imaged 15 min and 90-120 min later. Early and late images were interpreted individually and jointly. Twenty patients underwent (111)In-labeled leukocyte scintigraphy. Fourteen patients had infection: osteomyelitis (n = 7), vascular graft (n = 2), abscess (n = 2), joint replacement (n = 1), surgical wound (n = 1) and pneumonia (n = 1). There were 10 adverse events in six patients; all were mild and resolved spontaneously, and without any intervention. The sensitivity, specificity and accuracy were the same for both early and late imaging: 0.86, 0.81 and 0.83, respectively. Interpreting early and late images together did not improve the results. No relationship between peptide dose and study accuracy was found. In patients undergoing both examinations, the accuracies of the peptide and in vitro-labeled leukocyte imaging were identical: 0.80. In summary, 99mTc-P483H safely, rapidly and accurately detected focal infection, was comparable with in vitro-labeled leukocyte imaging and therefore merits further investigation.
Palestro
C J
CJ
Division of Nuclear Medicine of Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA. palestro@lij.edu
Weiland
F L
FL
Seabold
J E
JE
Valdivia
S
S
Tomas
M B
MB
Moyer
B R
BR
Baran
Y M
YM
Lister-James
J
J
Dean
R T
RT
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005189:False Positive Reactions; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D007239:Infections / Q000000981:diagnostic imaging*; D007962:Leukocytes / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010455:Peptides; D011506:Proteins / Q000008:administration & dosage / Q000009:adverse effects; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects
D015609:Organotechnetium Compounds; D010455:Peptides; D011506:Proteins; D019275:Radiopharmaceuticals; C100521:technetium Tc 99m P483H